智通财经APP获悉，美国基因治疗公司Bluebird Bio (BLUE.US)宣布计划裁员约四分之一，因为这家生物技术公司面临着基因疗法公司面临的困难环境。基因疗法是一种昂贵的一次性疗法，用于治疗难治性疾病。

截至6月底，bluebird bio拥有375名全职员工，本次裁员意味着将有近百名员工离开公司。 其实，在宣布裁员前，bluebird bio 就在其延迟的年度证券申报中预告，其可能没有足够的财务资源来继续运营一年。截至今年6月底，bluebird ...

Bluebird Bio Inc. announced plans to cut about a quarter of its workforce as the biotech confronts a difficult environment ...

(Nasdaq: BLUE) today announced that it has completed the filing of its Form 10-Q for the quarter ended June 30 ...

Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This ...

SOMERVILLE, Mass. (AP) — SOMERVILLE, Mass. (AP) — Bluebird Bio Inc. (BLUE) on Friday reported a loss of $81.4 million in its second quarter. The Somerville, Massachusetts-based company said it had a ...

美国基因治疗公司Bluebird ...

After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a ...

Gene therapy company Bluebird Bio on Tuesday announced a 25% reduction of its workforce as part of a restructuring.

9月24日，基因疗法公司蓝鸟生物(bluebird bio)宣布，公司将裁员25%，以求节约20%的现金消耗，帮助公司在2025年下半年达到现金流平衡。 截至6月底，bluebird bio拥有375名全职员工，本次裁员意味着将有近百名员工离开公司。

The company has not yet seen the financial payoff from its scientific breakthroughs — and it says it is continuing to lose ...

Gene therapy for sickle cell disease remains a tough business model — and may never work, @adamfeuerstein writes.